Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to -$67.0 million.

  • Celldex Therapeutics' Net Income towards Common Stockholders fell 5917.0% to -$67.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.5 million, marking a year-over-year decrease of 4573.49%. This contributed to the annual value of -$157.9 million for FY2024, which is 1164.61% down from last year.
  • Latest data reveals that Celldex Therapeutics reported Net Income towards Common Stockholders of -$67.0 million as of Q3 2025, which was down 5917.0% from -$56.6 million recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Net Income towards Common Stockholders ranged from a high of -$13.4 million in Q2 2021 and a low of -$67.0 million during Q3 2025
  • Over the past 5 years, Celldex Therapeutics' median Net Income towards Common Stockholders value was -$32.8 million (recorded in 2024), while the average stood at -$34.7 million.
  • Per our database at Business Quant, Celldex Therapeutics' Net Income towards Common Stockholders tumbled by 16922.9% in 2022 and then soared by 1528.16% in 2023.
  • Quarter analysis of 5 years shows Celldex Therapeutics' Net Income towards Common Stockholders stood at -$20.1 million in 2021, then crashed by 31.46% to -$26.5 million in 2022, then tumbled by 63.5% to -$43.3 million in 2023, then decreased by 8.76% to -$47.1 million in 2024, then tumbled by 42.34% to -$67.0 million in 2025.
  • Its Net Income towards Common Stockholders was -$67.0 million in Q3 2025, compared to -$56.6 million in Q2 2025 and -$53.8 million in Q1 2025.